Literature DB >> 15472349

In vitro antifungal susceptibility of Cryptococcus gattii.

Luciana Trilles1, Belkys Fernández-Torres, Márcia dos Santos Lazéra, Bodo Wanke, Josep Guarro.   

Abstract

We have determined the in vitro susceptibilities of 57 strains of Cryptococcus gattii to nine antifungal agents and have compared the MICs for these strains with those for C. neoformans. MICs were determined by a microdilution reference method. Albaconazole and ravuconazole (MICs of 0.04 and 0.05 microg/ml, respectively) showed the best activities. Micafungin showed no activity (MIC of >128 microg/ml). In general, C. gattii was less susceptible than C. neoformans to all drugs tested, with the exception of amphotericin B and flucytosine.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15472349      PMCID： PMC522305          DOI： 10.1128/JCM.42.10.4815-4817.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  22 in total

1.  In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole.

Authors:  S T Yildiran; M A Saracli; A W Fothergill; M G Rinaldi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-04       Impact factor: 3.267

2.  In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans.

Authors:  T Yamazumi; M A Pfaller; S A Messer; A Houston; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.

Authors:  M S Saag; R J Graybill; R A Larsen; P G Pappas; J R Perfect; W G Powderly; J D Sobel; W E Dismukes
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

4.  Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies.

Authors:  M Lozano-Chiu; V L Paetznick; M A Ghannoum; J H Rex
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

5.  Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group.

Authors:  S Chen; T Sorrell; G Nimmo; B Speed; B Currie; D Ellis; D Marriott; T Pfeiffer; D Parr; K Byth
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

6.  [Cryptococcosis in children in the State of Pará, Brazil].

Authors:  M do P Corrêa; E C Oliveira; R R Duarte; P P Pardal; F de M Oliveira; L C Severo
Journal:  Rev Soc Bras Med Trop       Date:  1999 Sep-Oct       Impact factor: 1.581

7.  Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan.

Authors:  Y C Chen; S C Chang; C C Shih; C C Hung; K T Luhbd; Y S Pan; W C Hsieh
Journal:  Diagn Microbiol Infect Dis       Date:  2000-03       Impact factor: 2.803

8.  In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.

Authors:  S Tawara; F Ikeda; K Maki; Y Morishita; K Otomo; N Teratani; T Goto; M Tomishima; H Ohki; A Yamada; K Kawabata; H Takasugi; K Sakane; H Tanaka; F Matsumoto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

9.  In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs.

Authors:  S P Franzot; J S Hamdan
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Clinical and host differences between infections with the two varieties of Cryptococcus neoformans.

Authors:  B Speed; D Dunt
Journal:  Clin Infect Dis       Date:  1995-07       Impact factor: 9.079
View more
  21 in total

1.  In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases.

Authors:  Luciana Trilles; Belkys Fernández-Torres; Márcia Dos Santos Lazéra; Bodo Wanke; Armando de Oliveira Schubach; Rodrigo de Almeida Paes; Isabel Inza; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Development of a singleplex PCR assay for rapid identification and differentiation of Cryptococcus neoformans var. grubii, Cryptococcus neoformans var. neoformans, Cryptococcus gattii, and hybrids.

Authors:  Xiaobo Feng; Xiaohua Fu; Bo Ling; Lei Wang; Wanqing Liao; Zhirong Yao
Journal:  J Clin Microbiol       Date:  2013-03-27       Impact factor: 5.948

3.  Heteroresistance of Cryptococcus gattii to fluconazole.

Authors:  A Varma; K J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

4.  Rapid identification of Cryptococcus neoformans and Cryptococcus gattii by matrix-assisted laser desorption ionization-time of flight mass spectrometry.

Authors:  Lisa R McTaggart; Eric Lei; Susan E Richardson; Linda Hoang; Annette Fothergill; Sean X Zhang
Journal:  J Clin Microbiol       Date:  2011-06-08       Impact factor: 5.948

5.  The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii.

Authors:  Shawn R Lockhart; Annette W Fothergill; Naureen Iqbal; Carol B Bolden; Nina T Grossman; Edward P Garvey; Stephen R Brand; William J Hoekstra; Robert J Schotzinger; Elizabeth Ottinger; Thomas F Patterson; Nathan P Wiederhold
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

Review 6.  Cryptococcus gattii infections.

Authors:  Sharon C-A Chen; Wieland Meyer; Tania C Sorrell
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

7.  Phenotypic switching in a Cryptococcus neoformans variety gattii strain is associated with changes in virulence and promotes dissemination to the central nervous system.

Authors:  N Jain; Li Li; D C McFadden; U Banarjee; X Wang; E Cook; B C Fries
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

8.  Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States.

Authors:  Naureen Iqbal; Emilio E DeBess; Ron Wohrle; Ben Sun; Randall J Nett; Angela M Ahlquist; Tom Chiller; Shawn R Lockhart
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

9.  Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.

Authors:  George R Thompson; Nathan P Wiederhold; Annette W Fothergill; Ana C Vallor; Brian L Wickes; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

10.  A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease.

Authors:  Tran Th Chau; Nguyen H Mai; Nguyen H Phu; Ho D Nghia; Ly V Chuong; Dinh X Sinh; Van A Duong; Pham T Diep; James I Campbell; Stephen Baker; Tran T Hien; David G Lalloo; Jeremy J Farrar; Jeremy N Day
Journal:  BMC Infect Dis       Date:  2010-07-09       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.